The Changing Face of Drug Resistant Tuberculosis
Guest Lecture by Dr. Dalene von Delft, Cape Town, South Africa
Visual Epidemiology, the Emory TB/HIV Research Group, Center for AIDS Research (CFAR), the Emory Global Health Institute, and the RSPH Departments of Epidemiology and Global Health are pleased to welcome Dr. Dalene von Delft from Cape Town, South Africa as she discusses the evolving epidemic of drug resistant tuberculosis. As a physician and former MDR-TB patient, Dr. von Delft offers unique perspectives from both clinical research and personal experience, and will discuss topics such as access to care, pressing issues, and drug development in the fight against drug resistance.
THIS EVENT WILL BE STREAMED ONLINE AND BE OFFERED TO THE PUBLIC!
Time and Date
Wednesday, March 19th 2014
Emory Rollins School of Public Health
Room CNR 1051
4:00 – 5:00 PM
(Refreshments provided)
About Dr. Dalene von Delft
DR. DALENE VON DELFT was a medical student in South Africa when she contracted multi-drug resistant tuberculosis (MDR-TB). Even with treatment, Dr. von Delft faced only a 42% cure rate of MDR among South Africans. The side effects of the medication were resulting in hearing loss and threatening her medical career. After over a year of treatment, she applied for and was granted ‘compassionate use’ for an experimental drug, bedaquiline, despite a questionably high all-cause mortality rate among those taking the drug. The new drug worked, and today she is fully cured and a practicing emergency-room physician. After her recovery, Dr. von Delft started the non-profit TB PROOF along with her doctor-husband, which was recently awarded the Centre for Global Health and Diplomacy Award for distinguished work in the field of global health diplomacy through USAID earlier this year.
